Mylan Pharmaceuticals introduces Temazepam Capsules USP, 7.5 mg

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Temazepam Capsules USP, 7.5 mg.

This additional strength, which had U.S. sales of approximately $56 million for the 12 months ending March 31, 2010, according to IMS Health, complements Mylan's already approved and marketed strengths, which are therapeutically equivalent to Mallinckrodt's Restoril® 15 mg, 22.5 mg and 30 mg for the short-term treatment of insomnia. The product is available for immediate shipment.

Currently, Mylan has 142 ANDAs pending FDA approval representing $95.6 billion in annual brand sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2009, according to IMS Health.

SOURCE Mylan Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care